Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I, Hibsh D, Kozol R, Efroni S, Ricken G, Wöhrer A, Haberler C, Hainfellner J, Krumpl G, Felzmann T, Dohnal AM, Marosi C, Visus C. Erhart F, et al. Among authors: felzmann t. Acta Neuropathol Commun. 2018 Dec 5;6(1):135. doi: 10.1186/s40478-018-0621-2. Acta Neuropathol Commun. 2018. PMID: 30518425 Free PMC article. Clinical Trial.
Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production.
Erhart F, Weiss T, Klingenbrunner S, Fischhuber K, Reitermaier R, Halfmann A, Blauensteiner B, Lötsch D, Spiegl-Kreinecker S, Berger W, Sialana FJ, Lubec G, Felzmann T, Dohnal A, Visus C. Erhart F, et al. Among authors: felzmann t. Cytotherapy. 2019 Jun;21(6):643-658. doi: 10.1016/j.jcyt.2019.03.002. Epub 2019 Apr 8. Cytotherapy. 2019. PMID: 30975602
Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.
Erhart F, Hackl M, Hahne H, Buchroithner J, Meng C, Klingenbrunner S, Reitermaier R, Fischhuber K, Skalicky S, Berger W, Spiegl-Kreinecker S, Lötsch D, Ricken G, Kuster B, Wöhrer A, Widhalm G, Hainfellner J, Felzmann T, Dohnal AM, Marosi C, Visus C. Erhart F, et al. Among authors: felzmann t. NPJ Vaccines. 2020 Jan 16;5(1):5. doi: 10.1038/s41541-019-0149-x. eCollection 2020. NPJ Vaccines. 2020. PMID: 31969991 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33446641
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.
Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Hoffermann M, Ruckser R, Rössler K, Spiegl-Kreinecker S, Fischer MB, Czech T, Visus C, Krumpl G, Felzmann T, Marosi C. Buchroithner J, et al. Among authors: felzmann t. Cancers (Basel). 2018 Oct 5;10(10):372. doi: 10.3390/cancers10100372. Cancers (Basel). 2018. PMID: 30301187 Free PMC article.
MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
Heugenhauser J, Galijasevic M, Mangesius S, Goebel G, Buchroithner J, Erhart F, Pichler J, Widhalm G, Stockhammer G, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Czech T, Surböck B, Urbanic Purkart T, Marosi C, Felzmann T, Nowosielski M. Heugenhauser J, et al. Among authors: felzmann t. Cancers (Basel). 2022 Mar 20;14(6):1579. doi: 10.3390/cancers14061579. Cancers (Basel). 2022. PMID: 35326730 Free PMC article.
40 results